series-a
Stage
1
Investors
About
Bitterroot Bio is a biotechnology company focused on developing immunotherapies for cardiovascular disease by targeting the CD47/SIRPα pathway to address atherosclerosis.
Explore Bitterroot Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.